drugset / Trial / NCT00005762
Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers
Treatment
Summary
The purpose of this study is to measure the blood levels of amprenavir (APV) alone, APV combined with efavirenz (EFV), and APV/EFV combined with a third drug (nelfinavir \[NFV\], indinavir \[IDV\], ritonavir soft gel capsules \[RTV sgc\], or saquinavir soft gel capsules \[SQV sgc\]). Anti-HIV therapy with 3 or 4 drugs is currently the recommended approach for treating HIV infections. Doctors need to know the best dosages of certain drugs when they are given in combination. This study will measure the blood levels of APV alone, APV combined with EFV, and APV/EFV plus a second PI in healthy volunteers. It will study the safety and tolerance of these drugs.
Timeline
- Start
- 2001-03
- Primary completion
- —
- Completion
- 2004-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amprenavir | Other / unclassified | — | — |
| Subject | Efavirenz | Other / unclassified | 600 mg | — |
| Subject | INDINAVIR ANHYDROUS | Other / unclassified | 1200 mg | — |
| Subject | Nelfinavir | Other / unclassified | 1250 mg | — |
| Subject | Ritonavir | Other / unclassified | 100 mg | — |
| Subject | Saquinavir | Small molecule | 1600 mg | — |